Difference in mode of action of cimetidine and gefarnate on endogenous prostacyclin, prostaglandin E2 and thromboxane in rat gastric mucosa

Tohoku J Exp Med. 1983 Aug;140(4):407-12. doi: 10.1620/tjem.140.407.

Abstract

The effects of cimetidine and gefarnate on endogenous prostacyclin, prostaglandin E2 and thromboxane were studied in vivo in rat gastric mucosa. The animals received cimetidine (20 mg/kg, i.p.) and/or gefarnate (100 mg/kg, s.c.) twice a day for 7 days. Gastric mucosal 6-keto-prostaglandin F1 alpha (as prostacyclin), prostaglandin E2 and thromboxane B2 (as thromboxane A2) were determined by radioimmunoassay. Cimetidine reduced prostacyclin, prostaglandin E2, but not thromboxane A2. Gefarnate inhibited the cimetidine-induced reduction of prostacyclin and prostaglandin E2; in cimetidine-untreated controls, it did not produce an increase in those prostaglandins and thromboxane A2 above the normal levels.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Cimetidine / antagonists & inhibitors
  • Cimetidine / pharmacology*
  • Depression, Chemical
  • Dinoprostone
  • Epoprostenol / metabolism*
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism*
  • Gefarnate / pharmacology*
  • Male
  • Prostaglandins E / metabolism*
  • Rats
  • Rats, Inbred Strains
  • Terpenes / pharmacology*
  • Thromboxanes / metabolism*

Substances

  • Prostaglandins E
  • Terpenes
  • Thromboxanes
  • Gefarnate
  • Cimetidine
  • Epoprostenol
  • Dinoprostone